"The U.S. Food and Drug Administration today approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pega"...
- Patient Information:
Details with Side Effects
Three patients received 10,000 IU/m2 of Oncaspar® (pegaspargase) as an intravenous infusion. One patient experienced a slight increase in liver enzymes. A second patient developed a rash 10 minutes after the start of the infusion, which was controlled with the administration of an antihistamine and by slowing down the infusion rate. A third patient did not experience any adverse reactions.
- History of serious allergic reactions to Oncaspar® (pegaspargase)
- History of serious thrombosis with prior L-asparaginase I therapy
- History of pancreatitis with prior L-asparaginase therapy
- History of serious hemorrhagic events with prior L-asparaginase therapy
Last reviewed on RxList: 3/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Oncaspar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.